Tobacco dependence is a significant health concern and the most preventable cause of death in the United States. Nicotine, the principal tobacco alkaloid, activates nicotinic receptors (nAChRs) on dopamine terminals in the mesolimbic and nigrostriatal systems to evoke dopamine release, leading to reward and tobacco dependence. Bupropion, which inhibits both neurotransmitter transporters and acts as a nAChR antagonist, has benefit as a smoking cessation agent. In addition, mecamylamine, a noncompetitive antagonist at both central and peripheral nAChRs, has shown benefit in clinical trials, but is limited by anticholinergic side effects because of its lack of nAChR selectivity. Bupropion and mecamylamine provide proof of concept that nAChR antagonists have efficacy in treating nicotine addiction; however, high relapse rates indicate a continuing need for alternative pharmacotherapies.
Our hypothesis is that discovery of selective antagonists targeted at neuronal nAChRs mediating nicotine-evoked neurotransmitter release, which mediates the reinforcing effects of nicotine, will provide clinically effective smoking cessation agents, circumventing unwanted side effects. The current pharmacological approach using a subtype-selective nAChR antagonist to block reversibly the specific nAChR subtype mediating the reinforcing effects of nicotine is similar to employing nAChR subunit deletion to prevent the expression of these nAChRs. In this regard, landmark work has shown that in β-2 subunit knockout mice, targeted injection into the ventral tegmental area of a lentiviral vector that efficiently expresses β-2 subunit protein, restores both nicotine-evoked dopamine release in the nucleus accumbens and nicotine reinforcement, providing convincing evidence that β-2-containing nAChRs expressed specifically in the ventral tegmental area are important in the reinforcing effects of nicotine (Molles et al, 2006).
Because nicotine interacts with all nAChR subtypes, discovery of subtype-selective nAChR antagonists that inhibit nicotine-evoked dopamine release was initiated using nicotine as the structural scaffold. Simple addition of an N-n-alkyl group converted nicotine from an agonist to an antagonist, and subtype selectivity began to emerge depending on the number of methylene groups in the n-alkyl chain (Dwoskin et al, 2004). The classic discovery that the bis-tri-alkylammonium nAChR channel blockers, hexamethonium and decamethonium, exhibit subtype selectivity between ganglionic and muscle-type nAChRs led us to use a similar approach by generating a sub-library of small molecules consisting of a bis-nicotinium analog structure, incorporating a variety of head groups and diverse linkers varying in length, unsaturation, and polarity. From this novel sub-library, a new lead compound, N,N′-dodecyl-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), emerged. bPiDDB potently inhibited nicotine-evoked dopamine release from superfused rat striatal slices (Dwoskin et al, 2008a). Using microdialysis, systemically administered bPiDDB also inhibited the nicotine-induced increase in extracellular dopamine in nucleus accumbens (Rahman et al, 2007). Thus, following in vitro and in vivo peripheral administration, bPiDDB decreased nicotine-evoked dopamine release. Utilizing radiolabeled bPiDDB, we also demonstrated its brain bioavailability by the blood–brain barrier choline transporter (Albayati et al, 2008).
Investigation of the behavioral pharmacology of bPiDDB revealed that this compound decreases nicotine-induced hyperactivity in nicotine-sensitized rats, a response associated previously with enhanced nicotine-evoked dopamine release in nucleus accumbens. Since bPiDDB did not reduce activity when administered alone in nicotine-sensitized rats, the decrease in nicotine-induced hyperactivity is not due to nonspecific motor impairment, but rather likely reflects inhibition of nicotine-evoked dopamine release. Moreover, bPiDDB decreases intravenous nicotine self-administration in rats (Neugebauer et al, 2006). Surprisingly, bPiDDB did not block the discriminative stimulus effects of nicotine, indicating that bPiDDB dissociates the rewarding and discriminative stimulus properties of nicotine (Dwoskin et al, 2008a). Following extinction of nicotine self-administration, bPiDDB also attenuated nicotine-induced reinstatement of nicotine-seeking behavior in rats (Dwoskin et al, 2008b). Taken together, the effectiveness of bPiDDB in decreasing both nicotine self-administration and reinstatement designates bPiDDB as a lead in our search for nAChR antagonists that may be a useful as treatments for tobacco dependence and relapse.
Albayati ZF, Dwoskin LP, Crooks PA (2008). Pharmacokinetics of the novel nicotinic receptor antagonist N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB). Drug Metab Dispos, PMID:18617603 [E-pub ahead of print, 10 July].
Dwoskin LP, Pivavarchyk M, Joyce BM, Neugebauer NM, Zheng G, Zhang Z et al (2008b). Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. 55th Annual Nebraska Symposium on Motivation: The Motivational Impact of Nicotine and its Role in Tobacco Use. In: RA Bevins and AR Caggiula (eds) Springer, in press.
Dwoskin LP, Sumithran SP, Zhu J, Deaciuc AG, Ayers JT, Crooks PA (2004). Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg Med Chem Lett 14: 1863–1867.
Dwoskin LP, Wooters TE, Sumithran SP, Siripurapu KB, Joyce BM, Lockman PR et al (2008a). N,N′-Alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: inhibition of nicotine-induced dopamine release and hyperactivity. J Pharmacol Exp Ther 326: 563–576.
Molles BE, Maskos U, Pons S, Besson M, Guiard P, Guilloux JP et al (2006). Targeted in vivo expression of nicotinic receptors in mouse brain using lentiviral expression vectors. J Mol Neurosci 30: 105–106.
Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT (2006). Effect of a novel nicotinic receptor antagonist, N,N′-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology 184:426–434.
Rahman S, Neugebauer NM, Zhang Z, Crooks PA, Dwoskin LP, Bardo MT (2007). The effects of a novel nicotinic receptor antagonist N,N-dodecane1,12-diyl-bis-3-picolinium dibromide (bPiDDB) on acute and repeated nicotine-induced increases in extracellular dopamine in rat nucleus accumbens. Neuropharmacology 52: 755–763.
This work was supported by NIH U19 DA017548, K02 DA00399, T32 DA007304.
DISCLOSURE/CONFLICT OF INTEREST
The University of Kentucky holds patents on N,N′-dodecyl-1,12-diyl-bis-3-picolinium dibromide. A potential royalty stream to LPD may occur consistent with University of Kentucky policy. The authors declare that over the past three years LD has received compensation from Boston University, Emory University, Meharry Medical College, the Universities of Arkansas, Florida, Indiana, Mississippi, Michigan, Nebraska, New Mexico as well as Yaupon Therapeutics Inc., and MB received compensation from Oregon Health Sciences University, University of Nebraska, University of Minnesota, Duke University, Morehead State University, Rutgers University, Medical College of Georgia, Centre College, Concordia University, Kansas University, University of Cincinnati, Yaupon Therapeutics, Inc., US World Meds and Targacept Inc.
About this article
Cite this article
Dwoskin, L., Bardo, M. Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse. Neuropsychopharmacol 34, 244–246 (2009). https://doi.org/10.1038/npp.2008.157